Connect with us

Technology

Alzheimer’s Drug Discovery Foundation’s Diagnostics Accelerator (DxA) invests $10M in Alamar Biosciences, Inc. to Advance Precision Medicine in Alzheimer’s Disease

Published

on

Largest DxA investment to date supports development of Alamar’s ARGO™ DX System and future in vitro diagnostic tests

NEW YORK and FREMONT, Calif., Jan. 8, 2025 /PRNewswire/ — The Alzheimer’s Drug Discovery Foundation (ADDF)‘s Diagnostics Accelerator (DxA) today announced a $10M investment in Alamar Biosciences, Inc. This landmark investment, the largest in DxA history, will expedite the translation of the ARGO-HT research platform into an FDA-cleared system to support the development of in vitro diagnostic (IVD) tests – the gold standard of diagnostics. Alamar’s ARGO HT System automates high-throughput NULISA™ assays, offering ultrasensitive protein detection and multiplexing for analyzing blood-based biomarkers related to Alzheimer’s and other dementias.

“In cancer and other diseases of aging, we have biomarker panels that allow clinicians to better differentiate from many underlying causes of the disease and more importantly, how to tailor treatments based on each patient’s individual biomarker profile,” said Howard Fillit, MD, Co-Founder and Chief Science Officer at the ADDF. “There is a pressing need to have biomarker panels for Alzheimer’s patients so we can better diagnose and develop new treatments. Alamar’s innovative platform provides the opportunity for a first of its kind blood panel in Alzheimer’s, which will be an important step as we move forward to delivering a more personalized approach for patients.”

“The powerful combination of ultra-high sensitivity and multiplexing unlocks the potential to measure novel biomarker signatures, enabling differential diagnosis in neurodegeneration,” said Niranjan Bose, Managing Director, Health and Life Sciences at Gates Ventures. “The investment in the development of ARGO DX focuses on translating this capability onto a scalable platform for widespread clinical use. We are excited to partner with the Alamar team to bring this vision to reality and advance the molecular diagnostics landscape in Alzheimer’s disease.”

The holy grail for Alzheimer’s diagnostics is to develop an accessible and scalable blood panel that can detect multiple biomarkers, providing clinicians with a better understanding of each patient’s individual disease biology. Alamar’s NULISA™ technology is unique in that it enables ultra-high sensitivity with the ability to test for multiple targets at once.

“Experts in the field have showcased the performance of the NULISA technology in detecting essentially all the important biomarkers in blood for Alzheimer’s and related dementias,” said Yuling Luo, Ph.D., Founder, Chairman, and CEO of Alamar Biosciences, Inc. “The ARGO DX platform can potentially revolutionize the biomarker space by allowing researchers to go from discovery to detection of biomarker panels that stratify patient subsets and disease factors that would otherwise have gone unnoticed.”

“A diagnostic platform such as Alamar’s, that can detect and measure multiple disease pathways, will be instrumental in paving the way for early detection, biology of aging-based differential diagnosis, allowing for a precision medicine approach in Alzheimer’s,” commented Dr. Fillit.

This recent investment in Alamar reflects the DxA’s larger vision to accelerate the development of new biomarkers and diagnostic tools to enable early detection and diagnosis of Alzheimer’s. To date, the DxA has invested more than $80 million in nearly 70 projects, underscoring its commitment to bringing accessible, affordable, and scalable diagnostics to patients struggling with Alzheimer’s disease. Along with blood tests, the DxA’s diverse portfolio includes retinal scans and digital tools that will not only provide patients with early and accurate diagnoses but also work in tandem and have the potential to be used for screening, prognostic, and prevention efforts. 

About The Alzheimer’s Drug Discovery Foundation (ADDF)
Founded in 1998 by Leonard A. and Ronald S. Lauder, the Alzheimer’s Drug Discovery Foundation is dedicated to rapidly accelerating the discovery of drugs to prevent, treat and cure Alzheimer’s disease. The ADDF is the only public charity solely focused on funding the development of drugs for Alzheimer’s, employing a venture philanthropy model to support research in academia and the biotech industry. The ADDF’s leadership and contributions to the field have played a pivotal role in bringing the first Alzheimer’s PET scan (Amyvid®) and blood test (PrecivityAD®) to market, as well as fueling the current robust and diverse drug pipeline. Through the generosity of its donors, the ADDF has awarded more than $360 million to fund over 760 Alzheimer’s drug discovery programs, biomarker programs and clinical trials in 21 countries. To learn more, please visit: http://www.alzdiscovery.org/.

ABOUT THE DIAGNOSTICS ACCELERATOR (DxA)
The Diagnostics Accelerator, created in July 2018, is a $100 million global research initiative from partners including ADDF Co-Founder Leonard A. Lauder, Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, among others, to develop novel biomarkers for the early detection of Alzheimer’s disease and related dementias.

This research initiative is dedicated to accelerating the development of affordable and accessible biomarkers to diagnose Alzheimer’s disease and related dementias and advance the clinical development of more targeted treatments. Through translational research awards and access to consulting support from industry experts, this program will challenge, assist and fund the research community in both academia and industry to develop novel peripheral and digital biomarkers.

About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/alzheimers-drug-discovery-foundations-diagnostics-accelerator-dxa-invests-10m-in-alamar-biosciences-inc-to-advance-precision-medicine-in-alzheimers-disease-302345929.html

SOURCE Alzheimer’s Drug Discovery Foundation

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

CHASM Exclusively Licenses AgeNT® Express Transparent Conductive Film to Mativ for Heated Glass Solutions

Published

on

By

CANTON, Mass., Jan. 9, 2025 /PRNewswire/ — Chasm Advanced Materials, Inc. (CHASM) and Mativ Holdings (Mativ), manufacturer of Argotec interlayer films for high-performance glazing, have announced an exclusive licensing agreement. CHASM’s AgeNT® Silver Nanowire (AgNW) and Carbon Nanotube (CNT) hybrid performance film technology will be licensed to Mativ for transparent heating solutions in advanced glass and window applications across architectural, military, and transportation segments.

This licensing agreement marks another milestone in the long-standing collaboration between Mativ and CHASM, aiming to accelerate the commercialization of a portfolio of AgeNT® Express films.

David Arthur, CEO and co-founder of CHASM, highlighted the significance of this partnership. “Licensing our AgeNT® Express technology to Mativ marks a major milestone for both companies,” said Arthur. “With CHASM’s leadership in CNT technology and flexible electronics, and Mativ’s expertise in roll-to-roll (R2R) precision coating and vast market reach in glazing applications, this collaboration is a powerful step toward CHASM’s expansion into global non-automotive glazing markets.”

“This agreement marks a significant milestone in the continued growth of Mativ within innovative and emerging markets,” states Mativ President and CEO Julie Schertell. “By becoming a licensee of Chasm’s groundbreaking AgNW and CNT technology, we reaffirm our position as leaders in material science innovation. Together, we are unlocking new potential in advanced film applications across top industrial sectors.”

About CHASM
CHASM’s mission is to develop and manufacture advanced carbon nano materials, leveraging its innovative product platforms to create a safer, more connected and sustainable world. The company’s patented nanotube manufacturing platform combined with its unique ability to integrate CNTs into product solutions is unleashing the power of nanotechnology.

Innovations powered by CHASM include universal transparent heaters for safer driving and a broad range of non-automotive applications, transparent antennas for smarter cities, conductive additives for EV batteries, and cement additives for greener (lower carbon footprint) concrete. 

CHASM is building the world’s largest multiwall CNT reactor (1,500 metric tons annual capacity) in Norman, Oklahoma, to produce NTeC® products to support battery and cement applications.

AgeNT, NTeC, CHASM, and the CHASM logo are trademarks of CHASM Advanced Materials, Inc.

About Mativ
Mativ Holdings, Inc. is a global leader in specialty materials, solving our customers’ most complex challenges by engineering bold, innovative solutions that connect, protect and purify our world. Headquartered in Alpharetta, Georgia, we manufacture on three continents and generate sales in over 100 countries through our family of business-to-business and consumer product brands. The company’s two operating segments, Filtration & Advanced Materials and Sustainable & Adhesive Solutions, target premium applications across diversified and growing categories. Our broad portfolio of technologies combines polymers, fibers and resins to optimize the performance of our customers’ products across multiple stages of the value chain. Our leading positions are a testament to our best-in-class global manufacturing, supply chain and materials science capabilities. We drive innovation and enhance performance, finding potential in the impossible. To learn more, visit mativ.com.

To learn more about Argotec glass interlayer films, visit argotec.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/chasm-exclusively-licenses-agent-express-transparent-conductive-film-to-mativ-for-heated-glass-solutions-302346673.html

SOURCE CHASM Advanced Materials

Continue Reading

Technology

Hettich Achieves Remarkable Success with Innovative Quora Ads Campaign

Published

on

By

MUMBAI, India, Jan. 9, 2025 /PRNewswire/ — Hettich, a leading manufacturer of innovative furniture fittings, built-in appliances, and door hardware solutions, has achieved outstanding results through a recent advertising campaign on Quora. The campaign aimed to enhance brand awareness and engagement among homeowners, interior designers/architects, and OEMs/builders, by showcasing Hettich’s cutting-edge products in a unique and compelling way.

Hettich’s campaign leveraged Quora’s targeted advertising solutions to reach specific demographics interested in home improvement and design. By focusing on audiences actively seeking quality and innovative solutions, the campaign effectively resonated with potential customers.

The Hettich campaign resulted in impressive metrics, including a view-through rate of 44.55% and 18,598 clicks from over 1 million views. With 2,357,070 impressions, Hettich significantly expanded its reach, fostering awareness and interest in its furniture fittings, built-in appliances, and door hardware.

Hettich crafted visually stunning and emotionally engaging content that spotlighted the unique features of its products through captivating storytelling and immersive video formats. The campaign vividly illustrated the transformative power of Hettich’s innovative solutions, seamlessly turning everyday moments into extraordinary experiences within living spaces. “We believe in the magic of storytelling to break through the advertising clutter,” said Aditya Jalgaonkar, AGM-Marketing, Hettich India. “This campaign reflects our commitment to creating meaningful, high-quality content that connects with our audience in a profound way.”

“At Quora, we are dedicated to helping brands tell their stories effectively and meaningfully,” said Gurmit Singh, General Manager at Quora APAC and MEA. “Hettich’s campaign is a perfect example of how targeted advertising can drive engagement and connect brands with their audiences. We’re thrilled to see the impact of our platform on Hettich’s marketing efforts.”

The success of Hettich’s campaign showcases the effectiveness of utilizing Quora’s targeted advertising capabilities. This partnership illustrates how brands can engage potential customers and create lasting connections through innovative marketing strategies.

About Quora

Quora is a platform that has 100 million monthly unique visitors in India, where people come to share knowledge and insights. By connecting brands with engaged audiences through targeted advertising, Quora helps businesses tell their stories effectively and meaningfully.

Photo: https://mma.prnewswire.com/media/2593402/Hettich_Quora_Ads.jpg
Logo: https://mma.prnewswire.com/media/2443578/Quora_Logo.jpg

 

View original content to download multimedia:https://www.prnewswire.com/in/news-releases/hettich-achieves-remarkable-success-with-innovative-quora-ads-campaign-302345570.html

Continue Reading

Technology

NX Taiwan Offers Work Experience to China University of Technology Students

Published

on

By

TOKYO, Jan. 9, 2025 /PRNewswire/ — Nippon Express (Taiwan) Co., Ltd. (hereinafter “NX Taiwan”), a group company of NIPPON EXPRESS HOLDINGS, INC., conducted a two-day work experience program for students from the China University of Technology (hereinafter “CUTe”) on Saturday, November 30, and Sunday, December 1.

NX Logo: https://kyodonewsprwire.jp/img/202412252272-O3-CT0nRnRv 

Photos

Group photo of participants: https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202412252272/_prw_PI1fl_AD0GB6Wy.jpg 

Warehouse work experience: https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202412252272/_prw_PI2fl_FTH84m7K.png 

The work experience program is part of the NX Group’s efforts to actively communicate with local communities and engage in community-based social contribution activities, recognizing its social and public mission as a logistics company.

Eighty students enrolled in CUTe’s Department of Marketing and Logistics took part in the program at NX Taiwan’s NEXT1 warehouse in Taoyuan City, where they received briefings from NEXT1 staff on basic logistics knowledge, safety, and warehouse operations. Through a combination of classroom lectures and hands-on experience, the students learned in depth about how warehouse operations are carried out.

The participants found the program a valuable opportunity to expand their practical knowledge and understanding of the logistics industry, with one commenting: “This experience has given me a deeper understanding of warehouse management and logistics, and strengthened my desire to work in the logistics industry, where I can contribute to society in the future.”

The NX Group will continue to actively engage in social contribution activities on a global scale to help develop human resources who can play active roles in the logistics industry.

About the NX Group: https://kyodonewsprwire.jp/attach/202412252272-O1-tne94err.pdf 

NX Group official website: https://www.nipponexpress.com/ 

NX Group’s official LinkedIn account:
https://www.linkedin.com/company/nippon-express-group/ 

View original content:https://www.prnewswire.com/apac/news-releases/nx-taiwan-offers-work-experience-to-china-university-of-technology-students-302346527.html

SOURCE NIPPON EXPRESS HOLDINGS, INC.

Continue Reading

Trending